Follow The Filings

BCAX Bicara Therapeutics Inc.

Health Care, filed as BICARA THERAPEUTICS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

Sold by 1 manager in 2026 Q2

  • 2 Owners
  • Max 2.3%
  • $25M
  • 1 reduce

In 2026 Q2 Nathan Fischel trimmed Bicara Therapeutics.

Who owns this now

Largest portfolio weights among holders, up to 2.3% (Palo Alto Investors). Not free-float ownership.

  1. Palo Alto Investors 2.3%
  2. Nathan Fischel Reduce 1.6%

Who owns BCAX

Sorted by value, long equity only, as of 2026 Q2.

History
Palo Alto Investors 2.3% Hold 550,408 $16M History
Nathan Fischel, Dafna Capital Management 1.6%, was 1.9% Reduce −32.4% 284,955 $8.5M History

2 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by BCAX's executives, directors and 10% owners in the last 12 months, from their Form 4s

All BCAX insider trades
  • $4.8M bought by 1 insider
  • None no sales outside a trading plan
  • $9.9M sold by 4 insiders under 10b5-1 plans
  1. Ryan Cohlhepp CEO
    Planned sale
    $401K 17,500 shares at $22.90 8.8% of stake
    Traded Sep 8 Filed Sep 10
    ↗
  2. Ivan Hyep CFO
    Planned sale
    $350K 12,500 shares at $27.97 8.8% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  3. Claire Mazumdar CEO
    Planned sale
    $280K 10,000 shares at $27.98 2.7% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  4. Ryan Cohlhepp COO
    Planned sale
    $525K 18,750 shares at $27.98 9.4% of stake
    Traded Aug 10 Filed Aug 12
    ↗
  5. Claire Mazumdar CEO
    Planned sale
    $284K 10,000 shares at $28.42 2.7% of stake
    Traded Jul 10 Filed Jul 14
    ↗
  6. Ryan Cohlhepp COO
    Planned sale
    $833K 28,750 shares at $28.98 14% of stake
    Traded Jul 8–9 Filed Jul 10
    ↗
  7. Ivan Hyep CFO
    Planned sale
    $808K 28,000 shares at $28.85 18% of stake
    Traded Jul 8 Filed Jul 10
    ↗
  8. Ivan Hyep CFO
    Planned sale
    $188K 9,200 shares at $20.42 6% of stake
    Traded May 21 Filed May 26
    ↗
  9. Claire Mazumdar CEO
    Planned sale
    $301K 15,000 shares at $20.04 4% of stake
    Traded May 18 Filed May 20
    ↗
  10. Ryan Cohlhepp COO
    Planned sale
    $254K 12,500 shares at $20.29 6.1% of stake
    Traded May 15 Filed May 18
    ↗
  11. David Raben Chief Medical Officer
    Planned sale
    $126K 5,500 shares at $22.88 9% of stake
    Traded Apr 27 Filed Apr 28
    ↗
  12. Ivan Hyep CFO
    Planned sale
    $212K 9,200 shares at $23.00 6% of stake
    Traded Apr 21 Filed Apr 22
    ↗
  13. Claire Mazumdar CEO
    Planned sale
    $354K 15,000 shares at $23.61 4% of stake
    Traded Apr 20 Filed Apr 20
    ↗
  14. Ryan Cohlhepp COO
    Planned sale
    $288K 12,500 shares at $23.01 6% of stake
    Traded Apr 15 Filed Apr 17
    ↗
  15. David Raben Chief Medical Officer
    Planned sale
    $104K 5,500 shares at $18.95 9% of stake
    Traded Mar 25 Filed Mar 26
    ↗

Also filed in the last 12 months, not counted as buying or selling: 47 option exercises.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
8-K 1.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,7.01,9.01 Filing Doc
SCHEDULE 13G — Filing Doc
8-K 5.07 Filing Doc
8-K 8.01,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc

Source: SEC EDGAR submissions, updated 14 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2024 FY2025
Net income -$68M -$137.95M

Balance sheet

Metric FY2024 FY2025
Total current assets $502.53M $422.05M
Total non-current assets * $7.46M $8.94M
Total assets $510M $430.99M
Total current liabilities $17.99M $28.95M
Total non-current liabilities * $131,000 $593,000
Total equity $491.88M $401.45M

Cash flow

Metric FY2024 FY2025
Cash from operations -$74.75M -$106.83M
Cash from investing -$0.009M -$318.45M
Cash from financing $334.03M $32.26M
Net change in cash $259.27M -$393.03M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.